Skip to main content
. 2019 Feb;36(Suppl 1):S22–S26.

TABLE 5.

Patient Outcomes: Multiple Myeloma and Prostate Cancer Subgroups

Outcomes, No. (%) Multiple Myeloma ZA Interval Dosing Prostate Cancer ZA Interval Dosing
Standard (n = 21) Extended (n = 7) P Standard (n = 100) Extended (n = 28) P
Skeletal-related event 9 (43) 1 (14) .172 28 (28) 7 (25) .753

Osteonecrosis of jaw 1 (5) 0 (0) .557 2 (2) 0 (0) .451

Abbreviation: ZA, zoledronic acid.